Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 6/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4664274 | 0.96 | EGFR (0.45) | LMNAEGFRKITMAPTTP53 | |
| Formic Acid SCHEMBL4666154 | 0.95 | LMNA (0.43) | LMNAEGFRKITMAPTTP53 | |
| Formic Acid SCHEMBL4665784 | 0.94 | ABL1 (0.45) | EGFRCCNT1CDK9ABL1BCR | |
| Formic Acid SCHEMBL4663939 | 0.94 | LMNA (0.46) | LMNAEGFRKITKDRABL1 | |
| Formic Acid SCHEMBL4665883 | 0.93 | LMNA (0.44) | LMNAEGFRKITMAPTTP53 | |
| Formic Acid SCHEMBL4667541 | 0.89 | EGFR (0.39) | EGFRKDRIKBKETBK1ABL1 | |
| Formic Acid SCHEMBL4665792 | 0.88 | PDE4D (0.48) | EGFRMAPTKDRCCNT1CDK9 | |
| Formic Acid SCHEMBL4665762 | 0.88 | EGFR (0.46) | EGFRABL1BCR | |
| Formic Acid SCHEMBL4665824 | 0.88 | SGK1 (0.41) | EGFRKDRIKBKETBK1ABL1 | |
| Formic Acid SCHEMBL4667479 | 0.87 | PIK3R1 (0.49) | EGFRKITTP53KDRIKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | LMNA 4261/4885EGFR 279/4885KIT 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.